The European Medicines Agency said on September 18 that Vertex Pharmaceuticals (Ireland) Limited had withdrawn applications to extend Kaftrio (ivacaftor/tezacaftor/elexacaftor) and Kalydeco (ivacaftor) to children aged one year and older with cystic fibrosis, used together as a combination regimen. The notice came in the CHMP highlights from the committee's September 14-17 meeting, which listed the pair among three already-authorised medicines whose indication-extension filings were pulled. Existing EU approvals for older patients are not themselves revoked by the withdrawals.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.